
Judges in California have ruled that Lilly should face claims it failed to fully disclose the extent of post-withdrawal side …

Lilly is enduring one of the bleakest financial years in its history as patent expiries continue to take chunks out …

The loss of patent on antidepressant Cymbalta in the US last December was largely responsible for Eli Lilly & Co’s …

Lilly posted a healthy set of financials at the end of July as the company looks to keep its growth …

Loss of exclusivity on Lilly’s blockbuster antipsychotic Zyprexa in 2011 continued to hit the company hard in the first quarter …
The loss of exclusivity on Eli Lilly’s blockbuster antipsychotic Zyprexa hit the company hard in 2012, with the firm’s overall …

Lundbeck has launched Sycrest in the UK for the treatment of acute attacks of bipolar I disorder. Sycrest (asenapine) is …

Lilly is forecasting a drop in revenue and profits for 2012, as it prepares for life without its blockbuster antipsychotic …
Sales rose 19% for Lilly in the third quarter of the year, with depression treatment Cymbalta leading the growth in …